Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI® (Lecanemab) For Early Alzheimer’s Disease

Canada’s health regulatory agency has issued a final positive recommendation supporting the public reimbursement of Leqembi® (lecanemab), a drug used to treat early Alzheimer’s disease. This marks a significant step toward broader access for patients across Canada, as government health programs consider coverage for the medication. The decision reflects a shift in policy aimed at addressing the growing burden of Alzheimer’s and neurodegenerative diseases in the country.

The Canadian Agency for Drugs and Technologies in Health (CADTH) has completed its review of Leqembi® and issued a recommendation in favor of public reimbursement. This follows the drug’s approval by Health Canada in late 2025, after which the agency assessed its clinical efficacy, safety profile, and cost-effectiveness. The recommendation is based on evidence suggesting that Leqembi® can slow cognitive decline in patients with early-stage Alzheimer’s, potentially improving quality of life and reducing long-term care costs.

While the recommendation is final, the implementation process is still underway. It is not yet clear which provinces or territories will adopt the reimbursement plan immediately, nor what the specific coverage criteria will be. Healthcare providers and patient advocacy groups are awaiting further guidance from federal and provincial health authorities on how to access the medication through publicly funded programs.

Implications for Alzheimer’s Patients and Healthcare Policy

This development could significantly improve access to Alzheimer’s treatment for thousands of Canadians, particularly those who cannot afford the medication privately. Public reimbursement may also influence the standard of care and prompt other countries to follow suit. However, questions remain regarding the scope of coverage, funding levels, and the timeline for rollout across different regions. The decision underscores the evolving landscape of neurodegenerative disease management and the government’s increasing willingness to fund innovative therapies.

Background on Leqembi® and Canadian Drug Policy

Leqembi® (lecanemab) received Health Canada approval in late 2025 after clinical trials demonstrated its ability to slow cognitive decline in early Alzheimer’s disease. The drug, developed by Eisai and Biogen, has been part of ongoing debates about cost, efficacy, and access to new Alzheimer’s therapies worldwide. In Canada, prior to this recommendation, access to similar treatments was limited, often requiring private insurance or out-of-pocket payments. The decision by CADTH to support public reimbursement reflects a broader trend of integrating innovative neurodegenerative treatments into publicly funded healthcare systems.

Search interest in Leqembi® and Alzheimer’s treatments has surged in recent months, driven by the drug’s regulatory approval and discussions about healthcare reform. However, the exact timing and scope of public coverage remain unconfirmed, leading to widespread anticipation among stakeholders.

Details on Implementation and Coverage Scope

It remains unclear how quickly provincial health authorities will adopt the recommendation and what specific criteria will be used for patient eligibility. The funding levels, distribution channels, and potential limitations are still under discussion. Additionally, it is not confirmed whether all provinces will uniformly implement the policy or if some regions may delay or modify coverage based on budget constraints or logistical considerations.

Next Steps for Policy Rollout and Access

The federal and provincial health agencies are expected to release detailed guidelines and coverage criteria in the coming weeks. Stakeholders, including healthcare providers, patient groups, and insurers, will monitor these developments closely. The timeline for full implementation across Canada remains uncertain, but early indications suggest a phased approach, starting with regions most prepared to adopt the new policy. Continued discussions about funding, access pathways, and patient eligibility are anticipated in the near term.

Key Questions

What does the final positive recommendation mean for patients?

The recommendation indicates that Leqembi® is now supported for public reimbursement, which could improve access for eligible patients, especially those unable to afford private treatment. However, actual access depends on subsequent policy implementation at the provincial level.

When will coverage become available across Canada?

The exact timeline is still uncertain. Provincial health authorities are expected to issue detailed guidelines soon, but full rollout may take several months or more, depending on regional readiness and funding decisions.

Will all provinces adopt this reimbursement policy?

It is not yet confirmed whether all provinces will implement the policy simultaneously. Adoption may vary based on regional budgets and priorities, with some regions potentially delaying or modifying coverage.

What are the potential benefits of this policy change?

Enhanced access to Leqembi® could slow disease progression in early Alzheimer’s patients, improve quality of life, and potentially reduce long-term healthcare costs associated with advanced care.

Are there any concerns or criticisms about this decision?

Some experts question the cost-effectiveness of Leqembi® and caution about potential side effects. Others highlight the need for clear implementation plans to ensure equitable access across different regions.

Source: primary